Jun 11, 2026 07:02AM
Jun 11, 2026 07:00AM
May 12, 2026 04:05PM
May 5, 2026 07:00AM
Mar 19, 2026 04:01PM
Mar 13, 2026 02:49PM
Mar 9, 2026 08:31AM Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD) following "home run with the 12-month data"
Mar 9, 2026 07:01AM
Mar 9, 2026 07:00AM
Mar 2, 2026 06:05AM
Jan 12, 2026 07:02AM
Jan 12, 2026 07:00AM
Dec 22, 2025 12:49AM
Dec 21, 2025 08:00PM Here's the list of top biotech stocks to own for 2026
Dec 3, 2025 07:30AM
Dec 3, 2025 07:30AM
Nov 13, 2025 04:01PM
Nov 4, 2025 07:01AM
Nov 4, 2025 07:01AM
Oct 7, 2025 07:30AM
Oct 7, 2025 07:30AM Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01
Sep 16, 2025 09:00AM
Sep 16, 2025 09:00AM
Sep 10, 2025 07:15AM
Sep 10, 2025 07:15AM
Aug 7, 2025 04:05PM
Jul 15, 2025 08:02AM
Jul 15, 2025 08:00AM Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01
Jun 17, 2025 07:00AM
May 12, 2025 04:01PM
Apr 28, 2025 01:39PM
Apr 28, 2025 01:38PM
Apr 27, 2025 09:00AM
Apr 24, 2025 08:00AM
Apr 14, 2025 08:41AM UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025
Apr 14, 2025 07:30AM
Mar 27, 2025 04:05PM
Mar 25, 2025 07:32AM
Mar 25, 2025 07:30AM
Feb 6, 2025 07:30AM
Feb 6, 2025 07:30AM
Jun 18, 2024 08:31AM Relmada Therapeutics (RLMD) Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017
Jun 18, 2024 08:30AM
Jan 9, 2023 08:01AM
Jan 9, 2023 08:00AM
Sep 20, 2022 08:30AM
Aug 11, 2022 04:15PM
Aug 9, 2022 08:31AM
Aug 9, 2022 08:30AM Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder
Feb 23, 2022 06:32AM

323,368 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All